Dealwatch: Sullivan & Cromwell’s City office and CC advise on nearly £6bn worth of deals

Sullivan & Cromwell’s City office has been busy this summer winning roles on two headline deals announced yesterday [8 September], working alongside Clifford Chance (CC) on both Cinven’s £2.3bn sale of pharmaceuticals group Amdipharm Mercury Company (AMCo) and advising Goldman Sachs on Mitsui Sumitomo’s £3.5bn Amlin purchase.

Continue reading “Dealwatch: Sullivan & Cromwell’s City office and CC advise on nearly £6bn worth of deals”

Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead

Cross-border teams from Sullivan & Cromwell and Latham & Watkins have landed the lead roles on the $40bn takeover of Allergan’s generic-making business by Teva that has seen the Israeli pharmaceutical powerhouse also abandon its bid for Mylan.

Continue reading “Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead”

Dealwatch: Linklaters and CC act on New Look sale as South African billionaire Wiese continues UK high street buy-up

Less than 30 days after advising on the £1.3bn purchase of Virgin Active by South African billionaire Christo Wiese’s private equity vehicle Brait, Linklaters‘ rising star Alex Woodward has led on Brait’s £780m deal for a 90% stake in clothing retailer New Look.

Continue reading “Dealwatch: Linklaters and CC act on New Look sale as South African billionaire Wiese continues UK high street buy-up”